Accsys Technologies

Company Update

All good news

The Q1 IMS contains a plethora of good news. Many of the items disclosed square with guidance at the time of the June preliminaries but they are welcome nevertheless, whilst there is a new plus in the form of a supply agreement with Medite for acetylated material (Tricoya) which should underpin an eventual move to a licensing agreement under the existing Joint Development Agreement (JDA).

- Highlights: Q1 underlying revenue growth of 12% for Accoya (adjusted to exclude Diamond Wood sales which halted in August 2010); a 4% gross manufacturing margin in Q1; and a Q1 cash outflow of only €1.0m. An agreement has also been reached for production of Medite Tricoya panels (durable class 1 MDF panels suitable for exterior use) with Accsys to supply 7,500 m3 of acetylated material to be used in these from its Arnhem plant over the next 17 months.

- The underlying revenue advance was aided by Accoya price rises (some at the start of CY 2011, some still being progressed) but underlying volume growth was 5-6%.

- The 4% gross manufacturing margin compares with the 4.2% loss (ex R&D and licensing costs) in 2010/11. The aim of a positive 2010/11 margin was flagged in June.

- The modest cash burn has been aided by the +ve gross manufacturing margin, the 16% reduction in other operating costs (expected given head count reductions/cost cutting measures) and the reduction in stocks flagged up in June. The first €2.2m tranche of monies from the Arnhem sale & leaseback deal was only banked in Q2.

- Accsys is to supply up to 7,500 m3 of acetylated material from its Arnhem plant to Medite, with the first shipments of Medite Tricoya to reach the market in FY 2010/11. This will enable final market testing and seeding prior to a possible license deal. The JDA has also been extended to grant Medite the exclusive right to make and sell Medite Tricoya in Holland, as well as in the UK and ROI.

- 7,500 m3 of acetylated material over 17 months equates to 5,294 m3 pa. To place this in perspective, Accsys sold 11,935 m3 of Accoya last year. So the supply agreement bodes well for future loss reduction as the Arnhem plant is more fully loaded. Forecasts are unchanged for now though as the sale price for the acetylated material is confidential and the timing of shipments to Medite has still to be clarified.

<table>
<thead>
<tr>
<th>Year to Mar</th>
<th>Sales (£m)</th>
<th>EBIT (£m)</th>
<th>EBITDA (£m)</th>
<th>PBT (£m)</th>
<th>EPS (£c)</th>
<th>Free Cash Flow (£m)</th>
<th>Net Cash/(Debt) (£m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011A</td>
<td>13.7</td>
<td>(14.00)</td>
<td>(12.10)</td>
<td>(14.0)</td>
<td>(0.07)</td>
<td>(19.0)</td>
<td>27.6</td>
</tr>
<tr>
<td>2012F</td>
<td>20.4</td>
<td>(11.30)</td>
<td>(9.40)</td>
<td>(10.7)</td>
<td>(0.03)</td>
<td>(7.1)</td>
<td>24.5</td>
</tr>
<tr>
<td>2013F</td>
<td>34.1</td>
<td>(7.90)</td>
<td>(5.60)</td>
<td>(7.6)</td>
<td>(0.02)</td>
<td>(18.4)</td>
<td>6.1</td>
</tr>
<tr>
<td>2014F</td>
<td>51.4</td>
<td>(0.50)</td>
<td>2.8</td>
<td>(0.4)</td>
<td>0.00</td>
<td>(2.0)</td>
<td>4.1</td>
</tr>
<tr>
<td>2015F</td>
<td>62.6</td>
<td>8.3</td>
<td>11.5</td>
<td>8.4</td>
<td>0.02</td>
<td>8.6</td>
<td>12.6</td>
</tr>
</tbody>
</table>

Source: Accsys Technologies (historical) and Numis Securities Research Department (forecast)

For FSA purposes this marketing communication has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Important disclosures relating to Numis Securities Limited are on pages 2 to 3 and include the analyst certification on page 2. For investment banking relationships, if any, with companies mentioned in the report, potential conflicts of interest and additional disclosures please refer to pages 2 to 3. When applicable, disclosures regarding ratings may be found at http://www.numiscorp.com/x/us/regulatory.html
The following disclosures are addressed to US-based recipients.

Analyst Certification

The research analyst who prepared this research report was Charles Pick. The analyst hereby certifies that all of the views expressed herein accurately reflect the analyst's personal views about any and all of the subject security and/or issuer at the date of original publication of this document.

The research analyst who prepared this research report also certifies that no part of the analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed by the analyst in the research report.

Important Disclosure

This research report has been prepared and approved by Numis Securities Limited ("Numis"), a securities dealer in the United Kingdom. Numis is not a registered broker-dealer in the United States and therefore is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided in the United States for distribution solely to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended. Any recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Numis Securities Inc. ("Numis Inc."). Numis Inc. may be contacted in writing or by phone: Numis Securities Inc., 275 Madison Avenue, 40th Floor, New York, NY 10016, U.S. phone (212) 277 7300. Numis Inc. is an affiliate of Numis. Under no circumstances should any recipient effect any transaction to buy or sell securities or related financial instruments through Numis.

Numis Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

Numis, Numis Inc. and/or their affiliates, directors, officers, and employees may have or have had interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the subject companies mentioned or referred to in this report.

The research analyst who prepared this research report receives compensation based upon various factors (such as the general perception of the analyst's ability and commitment to his/her analytical work) and upon the overall revenues including the investment banking revenues of Numis and/or one or more of its affiliates.

Accsys Technologies is or has been during the 12-month period preceding the date of this research report, a client of Numis.

Numis has received compensation for investment banking services from Accsys Technologies in the past 12 months.

Numis and/or one or more of its affiliates may receive or may seek to receive compensation for investment banking services from Accsys Technologies in the next 3 months.

Market Making

As at the date of this research report, Numis and/or one or more of its affiliates is making a market in Accsys Technologies.

Additional Disclosure

This Numis Securities Limited ("Numis") research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation, or particular needs of any specific recipient, even if sent only to a single recipient. This research report is offered solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell securities or related financial instruments, nor is it to be construed as a recommendation for Numis to effect any transaction to buy or sell securities or related financial instruments on behalf of any recipient. There is no express or implied understanding between Numis or Numis Securities Inc. ("Numis Inc.") and any recipient of this research report that Numis will receive any commission income in connection with this research report. The securities that may be described in this research report may not be eligible for sale in all jurisdictions or to certain categories of investors. This research report is based on information believed to be reliable, but it has not been independently verified and it is not guaranteed as being accurate. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Any statements or opinions expressed in this research report are subject to change without notice and Numis is not under any obligation to update or keep current the information contained herein. All statements and opinions expressed in this research report are made as of the date of this research report and are not held out as applicable thereafter. Neither Numis nor any of its directors, officers, employees, or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, provided that this shall not exclude liability to the extent that this is impermissible under the law relating to UK financial services.

Numis may rely on information barriers, such as "Chinese Walls", to control the flow of information within the areas, units, divisions, groups, or affiliates of Numis.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the regulation of the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign corporations are typically not subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

Past performance is not an indication or guarantee of future performance and no representation or warranty, express or implied, is made by Numis with respect to future performance. The value of any investment or income from any securities or related financial instruments discussed in this research report is subject to volatility and can fall as well as rise. Investors may not get back the full amount they originally invested. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from any securities or related financial instruments discussed in this research report.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Numis and Numis accepts no liability whatsoever for the actions of third parties in this respect.
The following disclosures are addressed to non-US-based recipients.

Regulatory Notice & Disclaimer

Numis regards this document as research. It has been approved under part IV article 19 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FPO”) by Numis Securities Limited (“Numis”) for communication in the United Kingdom only to investment professionals as that term is defined in article 19(5) of the FPO. Its contents are not directed at, may not be suitable for and should not be relied on by anyone who is not an investment professional including retail clients. Numis does not provide investment advisory services to retail clients. This research report is not directed at you if Numis is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Numis is permitted to provide research concerning investments to you under relevant legislation and regulations. This research report is not an offer or a solicitation to buy or sell any security. It does not constitute a personal recommendation and recipients must satisfy themselves that any dealing is appropriate in the light of their own understanding, appraisal of risk and reward, objectives, experience, and financial and operational resources. It has not been prepared in accordance with legal requirements designed to promote the independence of research. Non-independent research is not subject under the Markets in Financial Instruments Directive (“MiFID”) to any prohibition on dealing ahead of the dissemination of research. However, Numis is required by the FSA to have policies in place to manage the conflicts of interest which may arise in its production, which include preventing dealing ahead.

The prices of the investments referred to in this research report and the income from them may go down as well as up and investors may realise losses on them. Neither past performance nor forecasts are a reliable indicator of future results. Numis accepts no fiduciary duties to the reader of this research report and in communicating it, Numis is not acting in a fiduciary capacity. Neither Numis nor any of its directors, officers, employees or agents shall have any liability however arising, for any error, inaccuracy or incompleteness of fact or opinion in it or lack of care in its preparation or publication except where such is caused by its gross negligence, wilful default or fraud; nor shall it exclude or restrict any liability it has under the regulatory system to the extent that to do so is impermissible under the law relating to financial services.

All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. Research will carry the date of publication or, on research printed overnight, the date on which it was sent to the printers. Where a price is quoted in research it will generally, in the absence of contrary words, be the latest practicable price prior to distribution or, in the case of research printed overnight, the closing price at the close of business. Unless otherwise stated, prices in this research report are derived from quotations on the London Stock Exchange.

A list of significant items which could create a conflict of interest and other material interests in relation to research, together with Numis’s policy for managing such conflicts of interest, is set out on the Numis website (www.numiscorp.com/Regulatory.html).

Numis or one or more of its associates or a director or an employee of Numis or of an associate may from time to time have a position, or may have undertaken or may undertake an non-discretionary or related transaction, in a security referred to in this document or in a related security. Such a position or such a transaction may relate to the market making activities of Numis or to other activities of Numis.

Numis or one or more of its associates may from time to time have a position, or may have undertaken or may undertake an non-discretionary or related transaction, in a security referred to in this document or in a related security. Such a position or such a transaction may relate to the market making activities of Numis or to other activities of Numis.

A company covered in this research report has paid for an analyst’s reasonable expenses to visit their premises or offered modest hospitality or entertainment; further details are available on request.

Printed research will identify material sources; electronic research reports are normally based on company announcements made through the Regulatory Information Service. In those cases (but not otherwise) where the subject company has seen a draft of the research report and has suggested factual amendments which are incorporated by the researcher, this will be noted on the research. This applies normally only to printed pieces.

In printed research the risk warnings (if any) attaching to a particular company will be set out; in electronic pieces there is a cross-reference to the archive of research on the Numis website where, under the appropriate company name, details of such matters can be viewed.

The archive of research (available to all clients who normally receive Numis research) is available on the Numis website (www.numiscorp.com/ResearchMainresearch.html).

Numis accepts no responsibility whatever for any failure by a person resident outside the United Kingdom to observe the foregoing. No part of the content of any research material may be copied, forwarded or duplicated in any form or by any means without the prior consent of Numis and Numis accepts no liability whatsoever for the actions of third parties in this respect.

The following disclosures are addressed to non-US and non-UK-based recipients.

Valuation and Risks

For details relating to valuation and risks in printed research, please refer to the company comment contained herein. In electronic pieces of research please refer to the relevant company section of the Numis website http://www.numiscorp.com/us/research.html.

Ratings Key

In making a recommendation the analyst should compare his target price with the actual share price and then make a recommendation derived from the percentage thus calculated.

As from 14 February 2005, the formula is:

Buy > +20%
Add > +10% to +19.99%
Hold 0% to +/-9.99%
Reduce -10% to -19.99%
Sell > -20%

With effect from 9 February 2010 upon the initial establishment of a recommendation and target price for a company, an additional 10% deviation in the price from the default bands set out above is permitted before the recommendation has to be changed in subsequently published research documents.

Distribution of Ratings

<table>
<thead>
<tr>
<th>US Requirement 01/07/10 - 30/06/11</th>
<th>UK Requirement 01/04/11 - 30/06/11</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Securities Corporate Clients All Securities Corporate Clients</td>
<td></td>
</tr>
<tr>
<td>Buy</td>
<td>42.9%</td>
</tr>
<tr>
<td>Add</td>
<td>23.3%</td>
</tr>
<tr>
<td>Hold</td>
<td>29.0%</td>
</tr>
<tr>
<td>Reduce</td>
<td>3.8%</td>
</tr>
<tr>
<td>Sell</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

The above table shows the split of recommendations based on the last recommendation for each research stock during the last four calendar quarters.

The above table shows the split of recommendations based on all recommendations during the last calendar quarter for all securities and within each category the proportion of issuers to which Numis supplied material banking services.

For the split of recommendations by sector for the period from 1 Jan 2009 to 31 Dec 2009, please contact the Research Department of Numis Securities Limited.

The following graphs display the three year recommendation, target price and share price history for the subject corporation(s) of this research report. In those instances where the subject corporation(s) have been traded on the London Stock Exchange or Alternative Investment Market for less than three years, the graph will show the history since the date the subject corporation(s) were admitted to trading. Prices in the graph(s) below are in pence unless otherwise stated.

Three Year - Recommendation, Target Price, Share History

Accsys Technologies

<table>
<thead>
<tr>
<th>Buy</th>
<th>Add</th>
<th>Hold</th>
<th>Reduce</th>
<th>Sell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep'11</td>
<td>Oct'11</td>
<td>Nov'11</td>
<td>Dec'11</td>
<td>Apr'10</td>
</tr>
<tr>
<td>Recommendation</td>
<td>Price</td>
<td>Target Price</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Numis Securities Research Department